FIG:1


Evolution of CD4 blood cell count / µl
from start of the study
0
-20
-40
-60
-80
-100
-120
-140
-160
-180
Initial blood viral load
< 3log10
3log10-4log10
4log10-5log10
> 5log10
-31
-90
-52
-102
-68
-95
-83
-154
Composition of the invention
Placebo

FIG: 2


Mean difference in CD4 cell counts / µl
after 12 months of treatment
(Composition – Placebo)
0
10
20
30
40
50
60
70
80
90
< 280
281 - 329
330 - 379
> 380
Mean initial CD4 cell counts / µl

FIG: 3


Children
Adults
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
Percentage of patients
2
3
4
5
Number of infectious episodes

FIG. 4:


Children
Adults
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Percentage of patients
0
1
2
3
4
Number of infectious episodes

FIG. 5:


Placebo
Composition
Number of Malaria episodes
120
90
60
30
0
112
88
63
44
M01-M12
M06-M12

FIG: 6


Placebo
Composition
Number of Flu episodes
160
120
80
40
0
161
126
105
89
M01-M12
M06-M12

FIG : 7


Placebo
Composition
Number of Bronchitis episodes
50
25
0
21
10
46
36
M06-M12
M01-M12

FIG: 8


Placebo
Composition
Number of Intestinal infection episodes
120
90
60
30
0
71
56
112
96
M04-M12
M01-M12

FIG. 9A


Neutrophils in BALF
Neutrophils in BALF [x10^5]
Total cells in BALF
Total Cells in BALF [x10^5]
Non infected + IMT-A
Infected + IMT-A
Infected + IMT-A + Tamiflu
Infected + IMT-B
Infected + IMT-C
Infected + IMT-D
****

FIG : 9B


Macrophages in BALF
Macrophages in BALF [x10^5]
0
1
2
3
4
5
***
***
*
*
Non infected + IMT-A
Infected + IMT-A
Infected + IMT-A + Tamiflu
Infected + IMT-B
Infected + IMT-C
Infected + IMT-D
Lymphocytes in BALF
Lymphocytes in BALF [x10^5]
0.0
0.2
0.4
0.6
0.8
1.0
***
****
**
****
****
Non infected + IMT-A
Infected + IMT-A
Infected + IMT-A + Tamiflu
Infected + IMT-B
Infected + IMT-C
Infected + IMT-D

FIG : 10


Viral load (PFU x 10⁶ / ml)
0
10
20
30
40
-
VEHICLE
FLU
+
VEHICLE
FLU
+
TAMIFLU
FLU
+
IMT10
FLU
+
IMT100
FLU
+
IMT800

FIG : 11


Mean blood antibody titers to P27A
90000
75000
60000
45000
30000
15000
0
87480
42120
200
Alum
P27A
IMT 800
Alum
P27A
-
-
-
-
-